Showing 2491-2500 of 3223 results for "".
- Haag-Streit Launches Eyesi Indirect Ophthalmoscope ROP Simulator for Retinal Examinations on Preterm Infantshttps://modernod.com/news/haag-streit-launches-eyesi-indirect-ophthalmoscope-rop-simulator-for-retinal-examinations-on-preterm-infants/2482200/Haag-Streit has launched the Eyesi Indirect Ophthalmoscope ROP Simulator for training of retinal examinations on premature babies and classification of retinopathy of prematurity (ROP). The high-fidelity training system is designed to allow residents to practice device handling and
- Pandorum Technologies Secures $11 Million Investment to Advance its Regenerative Therapy for Corneal Blindness to Clinical Phasehttps://modernod.com/news/pandorum-technologies-secures-11-million-investment-to-advance-its-regenerative-therapy-for-corneal-blindness-to-clinical-phase/2482168/Pandorum Technologies announced the closure of a pre-Series B funding round, securing $11 million in investment to progress toward the first-in-human study of its flagship product, Kuragenx ("Liquid Cornea") to treat corneal blindness. The funding will also allow the
- SDC Transitions its Ophthalmic Biometric Division to Ora Inc.https://modernod.com/news/sdc-transitions-its-ophthalmic-biometric-division-to-ora-inc/2482149/Statistics & Data Corporation (SDC) has decided to transition its ophthalmic biometric division to its partner Ora Inc. Since 2005, SDC’s partnership and common ownership with Ora has provided clinical trial services in ophthalmology, while allowing S
- AcrySof IQ Vivity and Clareon Vivity EDOF IOLs Reach 1 Million Implants Milestonehttps://modernod.com/news/acrysof-iq-vivity-and-clareon-vivity-edof-iols-reach-1-million-implants-milestone/2482147/Alcon announced that the AcrySof IQ Vivity and Clareon Vivity extended depth of focus (EDOF) IOLs have surpassed more than 1 million implants worldwide. Vivity is the most implanted EDOF IOL globally, according to Alcon.[1] “We are proud to celebrate
- Oculis Provides Updates on Late-Stage Clinical Trials; Announces Leadership Appointmentshttps://modernod.com/news/oculis-provides-updates-on-late-stage-clinical-trials-announces-leadership-appointments/2482135/Oculis provided updates its late-stage clinical trials, and also announced senior appointments to its management and advisory teams. The announcements were made during it R&D Day on Wednesday, February 28. “2024 promises to be another exciting year for Ocu
- UC Irvine Study Shows Similarities and Differences in Human and Insect Vision Formationhttps://modernod.com/news/uc-irvine-study-shows-similarities-and-differences-in-human-and-insect-vision-formation/2482129/Researchers at the University of California, Irvine have discovered similarities and surprising differences between humans and insects in the production of the light-absorbing molecule of the retina, 11-cis-retinal, also known as the “visual chromophore,” according to a UC Irvine news
- AbbVie Appoints Robert A. Michael as Chief Executive Officerhttps://modernod.com/news/abbvie-appoints-robert-a-michael-as-chief-executive-officer/2482125/AbbVie, the parent company of Allergan, announced that its board of directors has unanimously selected Robert A. Michael, AbbVie's current president and chief operating officer, to succeed Richard A. Gonzalez as the company's chief executive officer (CEO). Mr. Gonzalez
- Opthea Completes Enrollment in First Pivotal Trial of Sozinibercept for Wet AMDhttps://modernod.com/news/opthea-completes-enrollment-in-first-pivotal-trial-with-sozinibercept/2482114/Opthea announced it has completed enrollment of all patients in the COAST phase 3 pivotal clinical trial investigating sozinibercept (OPT-302, a vascular endothelial growth factor (VEGF)-C/D inhibitor) in combination with aflibercept, an anti-VEGF-A therapy, for the treatment of wet age-rela
- Ocular Therapeutix Announces First Subjects Screened in Phase 3 Clinical Trial of Axpaxli in Wet AMDhttps://modernod.com/news/ocular-therapeutix-announces-first-subjects-screened-in-phase-3-pivotal-clinical-trial-of-axpaxli-in-wet-amd/2482113/Ocular Therapeutix announced that the first three subjects have been screened and received their first aflibercept injection in the phase 3 SOL-1 clinical trial of Axpaxli (axitinib intravitreal implant, also known as OTX-TKI) for the treatment of wet age-related macular degenerati
- Ocular Therapeutix Announces FDA Agreement to Amend SPA for Clinical Trial of Axpaxli in Wet AMDhttps://modernod.com/news/ocular-therapeutix-announces-fda-agreement-to-amend-spa-for-clinical-trial-of-axpaxli-in-wet-amd/2482079/Ocular Therapeutix announced that the FDA has agreed to a special protocol assessment (SPA) agreement modification for the company’s pivotal phase 3 SOL clinical trial of Axpaxli (axitinib intravitreal implant, also known as OTX-TKI) for the treatment of wet age-related